Precision Biosciences - DTIL STOCK NEWS

Precision BioSciences (DTIL) has accelerated its clinical development, expecting three new drug applications within three years targeting familial hypercholesterolemia, primary hyperoxaluria type 1, and chronic hepatitis B. A licensing agreement with iECURE aims to advance PBGENE-PCSK9 through Phase 1 trials, while preclinical data showcases their ARCUS genome editing platform's precision. The company has approximately $167 million in cash, sufficient to fund operations into 2023.

Precision BioSciences has partnered with iECURE to license its PCSK9-directed ARCUS nuclease, aiming to advance the PBGENE-PCSK9 candidate for treating familial hypercholesterolemia into Phase 1 clinical trials as early as 2022. Precision retains rights to all indications related to PBGENE-PCSK9 while iECURE gains access to develop therapies for four rare genetic liver diseases. Additionally, Precision will secure equity in iECURE and potential milestone and royalty payments from product sales.

Precision BioSciences (Nasdaq: DTIL) has secured an exclusive license from Tiziana Life Sciences (Nasdaq: TLSA) to utilize foralumab, a human anti-CD3 monoclonal antibody, as a lymphodepletion agent in its allogeneic CAR T therapy development. The collaboration aims to enhance the therapeutic effectiveness of CAR T cells by improving their tolerance and long-term persistence. Precision will oversee the development and commercialization of foralumab, providing Tiziana with upfront, milestone, and royalty payments.

Precision BioSciences, Inc. (NASDAQ: DTIL) announced its inaugural R&D event on September 9, 2021, at 8:00 am ET, focusing on in vivo gene editing. The event will feature management presentations and guest speakers, highlighting the company's development strategy and progress in in vivo gene editing projects. Attendees can expect insights on the ARCUS gene editing platform, pre-clinical data, and collaboration updates. Registration for the live webcast is available on the company’s investor website, with a replay accessible for one year post-event.

Precision BioSciences (Nasdaq: DTIL) reported strong financial results for Q2 ended June 30, 2021, with total revenues of $68.8 million, a significant increase from $1.1 million in Q2 2020. This surge was driven primarily by a $62.0 million revenue boost from the Servier Agreement. The company also noted a net income of $21.7 million compared to a net loss of $32.7 million in the prior year. R&D expenses rose to $37.2 million, reflecting ongoing investments in its ARCUS-edited CAR T programs. Additionally, Precision continues to advance its gene editing initiatives and has approximately $173.9 million in cash, sufficient to fund operations into 2023.

Precision BioSciences, Inc. (Nasdaq: DTIL) is set to release its financial results for Q2 2021 and provide a business update on August 12, 2021. The company focuses on developing allogeneic CAR T therapies and in vivo gene correction therapies through its proprietary ARCUS® genome editing platform. Designed for therapeutic safety and effectiveness, ARCUS underpins Precision's pipeline, which includes various CAR T immunotherapy candidates and in vivo gene correction therapies aimed at tackling genetic and infectious diseases.

Precision BioSciences, Inc. (Nasdaq: DTIL) has successfully dosed its first patient in a Phase 1 clinical trial of PBCAR19B, a promising allogeneic CAR T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL). This marks the company's fourth CAR T program, showcasing the versatility of its ARCUS genome editing platform. The trial aims to determine the maximum tolerated dose and assess safety, with an initial dose level starting at 2.7 × 10⁸ CAR T cells. Precision believes its immune-evading stealth cell technology will enhance treatment efficacy without prolonged immunosuppression.

Precision BioSciences (DTIL) and SpringWorks Therapeutics (SWTX) announced that the first patient has been dosed in their Phase 1/2a trial combining PBCAR269A, an allogeneic CAR T cell therapy targeting BCMA, with nirogacestat, a gamma secretase inhibitor, for treating relapsed/refractory multiple myeloma.

Precision is also gearing up to share interim results from monotherapy studies and plans to progress PBCAR269B into clinical trials in 2022, highlighting their commitment to developing innovative therapies.

Precision BioSciences Inc. (Nasdaq: DTIL) has made notable advancements in allogeneic CAR T therapies for relapsed/refractory non-Hodgkin lymphoma (NHL). Interim data from the Phase 1/2a study of PBCAR0191 reveal a 75% overall response rate and a 50% complete response rate among 12 patients treated with enhanced lymphodepletion (eLD). Additionally, preclinical results suggest that the new PBCAR19B stealth cell may effectively evade immune rejection. The FDA has accepted the investigational new drug application for PBCAR19B, which is now open for enrollment.